WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 350 participants.

Also called NCT03173534

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 350 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03173534
Other papers using this trial's data
  • Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation Circulation, 2024-03-05 DOI, PubMed 37874908

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03173534. Randomized; no masking; primary purpose prevention. Start 2017-12-15 (actual); primary completion 2022-12-06 (actual). Results posted on 2024-05-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
Condition
Aortic Valve Stenosis
Intervention (Device)
WATCHMAN
Lead sponsor
samir kapadia (class: other)
Collaborator
Boston Scientific Corporation (class: industry)
Collaborator
The Cleveland Clinic (class: other)

Record details

Record id
cardio:ct-nct03173534
Content hash
8a96dfcc0f1c74d98fc7709c5881fb5ef5919ac66ee41dbbbb03710508222c02